We are a clinical stage biopharmaceutical company focused on developing
innovative product candidates for the treatment or prevention of a wide range of
infections in hospital and non-hospital environments. Many of these infections
have become increasingly difficult to treat because of the rapid rise in drug
resistance. We have discovered and are developing a class of non-antibiotic
anti-infective compounds, which we have named Aganocide compounds. These
compounds are based upon small molecules that are naturally generated by white
blood cells when defending the body against invading pathogens. We believe that
our Aganocide compounds could form a platform on which to create a variety of
products to address differing needs in the treatment and prevention of bacterial
and viral infections. In laboratory testing, our Aganocide compounds have
demonstrated the ability to destroy all bacteria against which they have been
tested. ...

Quotes are delayed at least 15 minutes. All information provided "as is" for informational purposes only, not intended for trading purposes or advice.
EODData will not be liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein.
By accessing the EODData site, you agree not to redistribute the information found therein without EODData's consent.